Great Point Partners LLC
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), Great Point Partners LLC reported 29 stock positions worth $331.4 million. Its top holding was Neurogene (NGNE) at 12.7% of the portfolio, followed by Abivax SA-ADR (ABVX, 7.4%) and Pliant Therapeutics (PLRX, 6.5%). Compared with Q2 2024, it opened 5 new positions, sold out of 9, added to 3 and reduced 19. The biggest buy was Viridian Therapeutics (VRDN, shares +50%) and the biggest sale Urogen Pharma (URGN, shares −74%).
- Most Recent 13F
- Q2 2026
- Location
- Greenwich, CT
- CIK
- 0001281446
- Portfolio Value
- $331.4M (Q3 2024)
- SEC Filing
- 0001172661-24-004656 ↗ filed Nov 13, 2024
Holdings Value
Holdings 29 stocks · $331.4M
| NGNE Neurogene Inc. | 12.72% | 1,004,291 | $42.1M | No change |
| ABVX Abivax SA-ADR | 7.40% | 2,128,773 | $24.5M | Reduce -13.9% |
| PLRX Pliant Therapeutics Inc. | 6.46% | 1,910,121 | $21.4M | Reduce -27.6% |
| EOLS Evolus Inc. | 5.72% | 1,170,000 | $19.0M | Reduce -52.3% |
| VRDN Viridian Therapeutics Inc. | 5.15% | 750,000 | $17.1M | Add +50.0% |
| CYTK Cytokinetics Inc. | 5.03% | 316,000 | $16.7M | Reduce -33.4% |
| KALV Kalvista Pharmaceuticals Inc. | 4.54% | 1,299,503 | $15.0M | Reduce -2.9% |
| DVAX Dynavax Technologies Corp. | 4.46% | 1,326,234 | $14.8M | Reduce -44.1% |
| CNTX Context Therapeutics Inc. | 4.10% | 6,934,982 | $13.6M | Reduce -6.5% |
| ZURA Zura Bio Ltd. | 4.00% | 3,263,672 | $13.3M | Reduce -29.7% |
| ORKA Oruka Therapeutics Inc. | 3.81% | 514,659 | $12.6M | New |
| MRUS Merus NV | 3.77% | 250,000 | $12.5M | Reduce -52.2% |
| OLMA Olema Pharmaceuticals Inc. | 3.60% | 1,000,000 | $11.9M | Add +25.5% |
| IONS Ionis Pharmaceuticals Inc. | 3.08% | 255,000 | $10.2M | Reduce -22.7% |
| AUTL Autolus Therapeutics PLC | 3.08% | 2,811,955 | $10.2M | Reduce -18.3% |
| URGN Urogen Pharma Ltd. | 2.91% | 758,786 | $9.6M | Reduce -73.9% |
| OPTINOSE INC | 2.60% | 12,861,136 | $8.6M | Reduce -6.3% |
| ACLX Arcellx Inc. | 2.52% | 100,000 | $8.4M | Reduce -79.7% |
| DNTH Dianthus Therapeutics Inc. | 2.27% | 275,000 | $7.5M | Reduce -63.7% |
| OTLK Outlook Therapeutics Inc. | 2.08% | 1,293,028 | $6.9M | Reduce -24.0% |
| JSPR Jasper Therapeutics Inc. | 1.83% | 322,380 | $6.1M | Reduce -19.8% |
| VYGR Voyager Therapeutics Inc. | 1.69% | 959,953 | $5.6M | Reduce -40.1% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 1.58% | 500,000 | $5.2M | No change |
| TCRX Tscan Therapeutics Inc. | 1.53% | 1,016,375 | $5.1M | Add +8.0% |
| UNICYCIVE THERAPEUTICS INC | 1.05% | 8,559,000 | $3.5M | New |
| PMN Promis Neurosciences Inc. | 1.05% | 2,790,698 | $3.5M | New |
| RNAC Cartesian Therapeutics Inc. | 0.97% | 200,000 | $3.2M | New |
| VTGN Vistagen Therapeutics Inc. | 0.61% | 674,075 | $2.0M | Reduce -55.9% |
| CLYM Climb Bio Inc. filed as ELIEM THERAPEUTICS INC | 0.38% | 248,168 | $1.3M | New |
Options reported separately and not counted above: ACLX puts ($8.4M).
Portfolio Sells Q2 2024 → Q3 2024
| URGN Urogen Pharma Ltd. | Reduce -73.9% | 2.91% | −6.43 |
| INSM Insmed Inc. | Sold out | 0.00% | −3.21 |
| FOLD Amicus Therapeutics Inc. | Sold out | 0.00% | −2.84 |
| ACLX Arcellx Inc. | Reduce -79.7% | 2.52% | −2.68 |
| ESPR Esperion Therapeutics Inc. | Sold out | 0.00% | −2.46 |
| MRUS Merus NV | Reduce -52.2% | 3.77% | −2.16 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −1.50 |
| DNTH Dianthus Therapeutics Inc. | Reduce -63.7% | 2.27% | −1.49 |
| PBYI Puma Biotechnology Inc. | Sold out | 0.00% | −0.93 |
| VYGR Voyager Therapeutics Inc. | Reduce -40.1% | 1.69% | −0.73 |
| KYTX Kyverna Therapeutics Inc. | Sold out | 0.00% | −0.72 |
| DVAX Dynavax Technologies Corp. | Reduce -44.1% | 4.46% | −0.65 |
| SYRE Spyre Therapeutics Inc. | Sold out | 0.00% | −0.61 |
| VTGN Vistagen Therapeutics Inc. | Reduce -55.9% | 0.61% | −0.41 |
| OTLK Outlook Therapeutics Inc. | Reduce -24.0% | 2.08% | −0.32 |
| OPTINOSE INC | Reduce -6.3% | 2.60% | −0.13 |
| ANAB Anaptysbio Inc. | Sold out | 0.00% | −0.12 |
| LXRX Lexicon Pharmaceuticals Inc. | Sold out | 0.00% | −0.01 |
| IONS Ionis Pharmaceuticals Inc. | Reduce -22.7% | 3.08% | +0.07 |
| JSPR Jasper Therapeutics Inc. | Reduce -19.8% | 1.83% | +0.08 |
| CYTK Cytokinetics Inc. | Reduce -33.4% | 5.03% | +0.11 |
| EOLS Evolus Inc. | Reduce -52.3% | 5.72% | +0.62 |
| AUTL Autolus Therapeutics PLC | Reduce -18.3% | 3.08% | +0.79 |
| ZURA Zura Bio Ltd. | Reduce -29.7% | 4.00% | +0.89 |
| PLRX Pliant Therapeutics Inc. | Reduce -27.6% | 6.46% | +1.03 |
| ABVX Abivax SA-ADR | Reduce -13.9% | 7.40% | +1.14 |
| CNTX Context Therapeutics Inc. | Reduce -6.5% | 4.10% | +1.25 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -2.9% | 4.54% | +1.52 |
Portfolio Buys Q2 2024 → Q3 2024
| VRDN Viridian Therapeutics Inc. | Add +50.0% | 5.15% | +3.90 |
| ORKA Oruka Therapeutics Inc. | New | 3.81% | +3.81 |
| OLMA Olema Pharmaceuticals Inc. | Add +25.5% | 3.60% | +1.95 |
| UNICYCIVE THERAPEUTICS INC | New | 1.05% | +1.05 |
| PMN Promis Neurosciences Inc. | New | 1.05% | +1.05 |
| RNAC Cartesian Therapeutics Inc. | New | 0.97% | +0.97 |
| TCRX Tscan Therapeutics Inc. | Add +8.0% | 1.53% | +0.47 |
| CLYM Climb Bio Inc. | New | 0.38% | +0.38 |
Options Activity Q2 2024 → Q3 2024
| ACLX Arcellx Inc. | put | New | 100,000 | $8.4M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 37 | $424.4M | VOR, ABVX, VERA, ZURA, ALMS |
| Q1 2026 | 39 | $408.3M | APGE, VOR, ZURA, AMLX, NKTR |
| Q4 2025 | 29 | $308.4M | APGE, AMLX, ZURA, IRON, RAPT |
| Q3 2025 | 28 | $239.5M | AMLX, RZLT, NKTR, ZURA, SLNO |
| Q2 2025 | 26 | $153.8M | IONS, RZLT, AMLX, LEGN, ABVX |
| Q1 2025 | 31 | $184.0M | CYTK, KALV, EOLS, ABVX, VRDN |
| Q4 2024 | 26 | $212.2M | IONS, CYTK, KALV, VRDN, PLRX |
| Q3 2024 | 29 | $331.4M | NGNE, ABVX, PLRX, EOLS, VRDN |
| Q2 2024 | 33 | $522.0M | URGN, NGNE, ABVX, MRUS, PLRX |
| Q1 2024 | 35 | $641.6M | NGNE, ALPN, URGN, ABVX, EOLS |